TechConnect


Lophius Biosciences GmbH Joins NEU² and Receives Substantial Grant Funding for the Diagnosis and Monitoring of Multiple Sclerosis

June 23, 2013 07:42 AM EST By: Jennifer Rocha

NEU² Consortium is a Germany public-private partnership dedicated to finding advanced treatments for MS.

Story content courtesy of B3C Newswire, DE

The project is addressing the development of T-Track® MS as a novel blood-based diagnostic test supporting the initial diagnosis of multiple sclerosis (MS) and enabling the monitoring of MS disease progression. This new project is to last for about two years with a funding of > 350.000 EUR proportionally supplied by The Federal Ministry of Education and Research (BMBF) under the BioPharma initiative.

Lophius Biosciences is a leading developer of innovative T cell based diagnostic test systems. One of the company’s platform technologies, the “Reverse T Cell Technology (RTT)”, represents a novel strategy for the diagnosis of T cell-mediated diseases.  Due to the high specificity of RTT for activated Th cells, the intended use of the RTT assay is the reliable detection of disease-specific activated Th cells as a novel biomarker for the diagnosis and monitoring of ongoing autoimmune diseases such as MS.

Initial data from a collaboration between Lophius Biosciences and the Clinic and Policlinic for Neurology, University of Regensburg, and the Institute for Neuroimmunology and Clinical MS Research, Center for Molecular Neurobiology Hamburg, demonstrated preliminary clinical proof of principle for this MS test.

 

Subscribe to our mailing list, and we'll keep you posted of the latest developments.

RSS feed of TechConnect News™ RSS feed of TechConnect News™

Annual Meeting

TechConnect World 2014
Washington, DC, June 15-18, 2014
 

Event Spotlight

NISS 2014
Washington, DC, June 15-18, 2014
NSBIRC 2014
Washington, DC, June 16-18, 2014
APCE 2014
Honolulu, Hawaii, September 15-17, 2014
DES
Austin, TX, November 11-14, 2014


© TechConnect. All Rights Reserved. Disclaimer
Terms of Use | Privacy Policy | Contact Us | Site Map